Bacillus (e.g., B. Subtilis, B. Thuringiensis, Etc.) Patents (Class 435/252.31)
-
Publication number: 20140271676Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Clark PAN, Huawei QIU
-
Publication number: 20140272932Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
-
Publication number: 20140274782Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
-
Publication number: 20140273110Abstract: Bacteria that run the beta oxidation cycle in reverse anabolic direction are provided, along with many novel primers to start the reverse cycle, pathways to make such primers, and a large variety of products produced thereby. Methods for making desired product by using such primers in the reverse pathway are also disclosed.Type: ApplicationFiled: March 6, 2014Publication date: September 18, 2014Applicant: William Marsh Rice UniversityInventors: Ramon GONZALEZ, James M. CLOMBURG
-
Publication number: 20140273237Abstract: Methods of constructing a cell comprising in its chromosome one or more copies of an open reading frame (ORF) or operon encoding at least one polypeptide of interest, each copy being under the transcriptional control of a heterologous promoter using a site specific recombinase and in vivo integration by recombination; means for carrying out the methods, resulting cells, and methods for producing a polypeptide of interest using the resulting cells.Type: ApplicationFiled: March 20, 2014Publication date: September 18, 2014Applicant: Novozymes A/SInventors: Anne Breuner, Michael Dolberg Rasmussen
-
Publication number: 20140271699Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Peter Kwong, Barney Graham, Jason McLellan, Jeffrey Boyington, Ivelin Stefanov Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Marie Pancera, Cinque Soto, Sanjay Srivatsan, Baoshan Zhang
-
Publication number: 20140274707Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins, formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth and for protecting plants from pathogens by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plant roots.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Spogen Biotech Inc.Inventors: Brian Thompson, Katie Thompson
-
Publication number: 20140273204Abstract: The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Publication number: 20140273129Abstract: Provided herein are glycerol-3-phosphate dehydrogenase (GPD) enzymes with increased KM for NADH and GPD enzymes with substantially the same affinity for NADH and NADPH and/or are feedback inhibited by glycerol-3-phosphate. Also provided herein are recombinant microorganisms comprising a heterologous gene encoding GPD and a deletion or disruption in an endogenous gene encoding GPD. Also provided are recombinant microorganisms comprising a heterologous gene encoding GPD and a butanol biosynthetic pathway. Further provided are methods of producing butanol comprising providing the recombinant microorganisms described herein and contacting the recombinant microorganism with at least one fermentable carbon substrate under conditions wherein butanol is produced.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: BUTAMAX ADVANCED BIOFUELS LLCInventors: Ritu Bhalla, Gopal K. Chotani, Michael Dauner, Mark J. Nelson, Daniel P. O'keefe, Caroline M. Peres, Jahnavi Chandra Prasad, Jean-Francois Tomb
-
Publication number: 20140271641Abstract: The invention features thrombospondin-1 (TSP-1) polypeptides (e.g., 3TSR-Fc fusion proteins), nucleic acid molecules encoding the TSP-1 polypeptides, and compositions thereof. The invention also features methods of making and using the TSP-1 polypeptides of the invention (e.g., using 3TSR-Fc fusion proteins to treat a subject having a disorder associated with pathological angiogenesis, e.g., cancer, e.g., epithelial ovarian cancer (EOC)).Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicants: University of Guelph, Beth Israel Deaconess Medical Center, Inc.Inventors: John W. LAWLER, Mark Duquette, James Petrik
-
Publication number: 20140271700Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
-
Publication number: 20140273122Abstract: The invention provides a microorganism of the genus Bacillus, including one or more gene(s) selected from a group consisting of a gene conferring thiolase activity, a gene conferring CoA transferase activity and a gene conferring acetoacetate decarboxylase activity, wherein the microorganism produces acetone.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MITSUI CHEMICALS, INC.Inventors: Dominik Lukas JÜRGEN-LOHMANN, Su Sun Chong, Anjali Madhavan, Katsuyuki Takahashi
-
Publication number: 20140273089Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: AMGEN, INC.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Publication number: 20140273119Abstract: Provided are isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 30, 2012Publication date: September 18, 2014Inventors: Ye Liu, Lan Tang, Yu Zhang, Junxin Duan
-
Publication number: 20140273161Abstract: The invention provides a system of heavy metal sequestration by bacteria. The bacteria expresses the ppk, mt, and/or ?-galactosidase (lacZ) genes and can tolerate at least 25 ?M mercury, 1,000 ?M zinc, 250 ?M cadmium, and 3,000 ?M Pb. The system allows for facile determination of the presence of heavy metal contaminants in a liquid and the facile collection of the bacteria that has sequestered large amounts of heavy metal. Further provided is a system of gene expression in bacteria that comprises phage and plastid gene expression elements and delivers a particularly high level of protein expression and heavy metal resistance.Type: ApplicationFiled: May 30, 2014Publication date: September 18, 2014Applicant: Inter American University of Puerto RicoInventor: Oscar N. Ruiz
-
Publication number: 20140275490Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:5, 9, 13, 17, 21, 25 or 29 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:7, 11, 15, 19, 23, 27 or 31.Type: ApplicationFiled: March 30, 2012Publication date: September 18, 2014Applicant: Astellas Pharma Inc.Inventors: Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
-
Publication number: 20140255410Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: September 11, 2014Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20140255997Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 11, 2012Publication date: September 11, 2014Inventors: Esben Peter Friis, Leonardo De Maria, Jesper Vind, Thomas A. Poulsen, Allan Svendsen, Steffen Danielsen, Rolf T. Lenhard, Henrik Friis-Madsen, Lars K. Skov
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140256009Abstract: Described is a method for the enzymatic production of butadiene which allows to produce butadiene from crotyl alcohol. Also described are enzyme combinations and compositions containing such enzyme combinations which allow the enzymatic conversion of crotyl alcohol into butadiene. Furthermore, the invention relates to microorganisms which have been genetically modified so as to be able to produce butadiene from crotyl alcohol. Moreover, the invention relates to a method for the enzymatic production of crotyl alcohol from crotonyl-Coenzyme A. The obtained crotyl alcohol can be further converted into butadiene as described herein. Also described are enzyme combinations which allow to convert crotonyl-Coenzyme A into crotyl alcohol as well as (micro)organisms which express such enzyme combinations.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Applicant: SCIENTIST OF FORTUNE, S.A.Inventor: Philippe Marliere
-
Publication number: 20140256930Abstract: An object of the present invention is to provide a method for converting the coenzyme dependency of enzymes of the medium-chain dehydrogenase/reductase (MDR) family. A further object of the present invention is to provide enzyme variants of the MDR family whose coenzyme dependency is converted by the conversion method and a method for enzymatically producing optically active alcohols using the enzymes. The present inventors developed a novel enzyme conversion method for converting the coenzyme dependency of enzymes of the MDR family, rationally designed enzyme variants that are altered by the enzyme conversion method to be able to use NADPH as a coenzyme from a useful enzyme of the MDR family that uses NADH as a coenzyme, and actually provide variants having such an ability.Type: ApplicationFiled: June 27, 2012Publication date: September 11, 2014Applicant: KANEKA CORPORATIONInventors: Shinichi Yoshida, Shunichi Taira, Masakatsu Nishihachijyo, Masutoshi Nojiri, Shigeru Kawano
-
Publication number: 20140248254Abstract: This invention provides the use of AChE as nuclease. The use of AChE in regulating the stability of nucleic acid and cell apoptosis, as well as a series of agents based on the use, including the agents for promoting or inhibiting cell apoptosis, the agents for inhibiting tumors, and the agents for protecting nucleic acid from impairing, are provided.Type: ApplicationFiled: August 8, 2012Publication date: September 4, 2014Applicant: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCESInventors: Xuejun Zhang, Jing Xie, Aiying Du, Kaijie Guo, Jun Wu
-
Publication number: 20140248283Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: ALPER BIOTECH, LLCInventor: Özge Alper
-
Publication number: 20140248663Abstract: Provided are isolated polypeptides having cellobiohydrolase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 15, 2012Publication date: September 4, 2014Inventors: Lan Tang, Junxin Duan, Yu Zhang, Ye Liu
-
Publication number: 20140248673Abstract: This document describes biochemical pathways for producing pimelic acid, 7-hydroxyheptanoic acid, 7-aminoheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the CoA-dependent elongation enzymes or analog enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.Type: ApplicationFiled: December 13, 2013Publication date: September 4, 2014Applicant: INVISTA North America S.á r.I.Inventors: Adriana Leonora Botes, Alex Van Eck Conradie
-
Publication number: 20140248397Abstract: A variant polypeptide having alpha-amylase activity, wherein the variant has an amino acid sequence which, when aligned with the alpha-amylase comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids 4, 6, 13, 14, 15, 16, 20, 45, 47, 51, 54, 61, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 80, 82, 87, 88, 94, 95, 100, 103, 104, 117, 124, 125, 126, 128, 130, 133, 134, 136, 143, 144, 146, 168, 174, 177, 178, 183, 186, 188, 189, 190, 194, 195, 199, 200, 201, 204, 207, 210, 214, 217, 219, 222, 225, 227, 233, 234, 235, 236, 240, 251, 252, 254, 258, 259, 260, 261, 262, 263, 264, 266, 267, 269, 271, 273, 281, 282, 283, 284, 286, 288, 299, 322, 323, 325, 327, 328, 331, 334, 350, 356, 358, 367, 370, 371, 374, 377, 378, 388, 391, 414, 421, 422, 445, 450, 467, 488, 505, 536, 548, 583, 588, 603, 637, 648, 651, 652, 660, 676, 677, said positions being defined with reference to SEQ ID NO: 2 and wherein the variant has one or more altered prType: ApplicationFiled: March 15, 2013Publication date: September 4, 2014Applicant: DSM IP ASSETS B.V.Inventors: Rene Marcel DE JONG, Hanna Elisabet ABBAS
-
Publication number: 20140242655Abstract: Embodiments of the present invention relate to methods for the biosynthesis of di- or trifunctional C7 alkanes in the presence of isolated enzymes or in the presence of a recombinant host cell expressing those enzymes. The di- or trifunctional C7 alkanes are useful as intermediates in the production of nylon-7, nylon-7,x, nylon-x,7, and polyesters.Type: ApplicationFiled: June 29, 2012Publication date: August 28, 2014Applicant: INVISTA TECHNOLOGIES S.A R.L.Inventors: Paul S. Pearlman, Changlin Chen, Adriana Leonora Botes, Alex Van Eck Conradie, Benjamin D. Herzog
-
Publication number: 20140242651Abstract: The present invention relates to a biocatalytic method of preparing a mono-acylated polyol catalyzed by triacylglycerol lipase mutants, as for example derived from Candida antarctica lipase B (CALB); a biocatalytic method of enantioselectively preparing an asymmetric mono-acylated polyol, catalyzed by the same enzyme mutants; as well as the use of a mutated triacylglycerol lipase in a method of preparing mono-acylated polyols. The invention also provides novel mutants, coding sequences thereof, and recombinant microorganisms carrying said coding sequences.Type: ApplicationFiled: March 20, 2014Publication date: August 28, 2014Applicant: BASF SEInventors: Bernhard Hauer, Cecilia Kvarnström Branneby, Karl Hult, Anders Magnusson, Anders Hamberg
-
Publication number: 20140234941Abstract: The present invention provides a novel phosphatidic acid phosphatase gene. The object of the present invention can be solved by providing a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5; a protein comprising the amino acid sequence set forth in SEQ ID NO: 2; and mutants thereof.Type: ApplicationFiled: July 27, 2012Publication date: August 21, 2014Applicant: SUNTORY HOLDINGS LIMITEDInventor: Misa Ochiai
-
Publication number: 20140234313Abstract: The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired VL and VH domains that demonstrate soluble expression and folding in a reducing or intracellular environment. The invention also relates to polynucleotides encoding such polypeptides, to libraries of such polypeptides or polynucleotides, and to methods of using such polypeptides in research, diagnostic and therapeutic applications.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Affinity Biosciences Pty LtdInventors: Matthew David Beasley, Keith Philip Niven, Ben Ross Kiefel
-
Publication number: 20140234897Abstract: Disclosed are isolated polypeptides having cellobiohydrolase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Furthermore, nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains are disclosed.Type: ApplicationFiled: November 2, 2012Publication date: August 21, 2014Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140234906Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 17, 2012Publication date: August 21, 2014Inventors: Carsten Andersen, Signe Eskildsen Larsen, Esben Peter Friis, Peter Kamp Hansen, Henrik Friis Madsen, Anders Viksoe Nielsen, Pernille Ollendorf Micheelsen
-
Publication number: 20140234907Abstract: Provided are isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: August 21, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Ye Liu, Junxin Duan, Lan Tang
-
Publication number: 20140234214Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 14, 2014Publication date: August 21, 2014Applicant: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Publication number: 20140234231Abstract: Isolated ?-glucanases from Hypocrea tawa, Trichoderma reesei, and Trichoderma konilangbra are described, as well as oral care compositions containing the same. The oral care composition may be employed to prevent or reduce dental plaque.Type: ApplicationFiled: February 27, 2014Publication date: August 21, 2014Applicant: DANISCO US INC.Inventors: Steven Kim, Suzanne Lantz, Michael Pepsin
-
Publication number: 20140234918Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 10, 2012Publication date: August 21, 2014Applicant: Novozymes A/SInventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140234945Abstract: The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.Type: ApplicationFiled: January 16, 2014Publication date: August 21, 2014Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Fei XIONG
-
Publication number: 20140237632Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: ApplicationFiled: January 21, 2014Publication date: August 21, 2014Inventors: BROOKE BEVIS, BENJAMIN GLICK
-
Publication number: 20140234924Abstract: The present invention provides methods of designing and generating glycerol dehydrogenase (GlyDH) variants that have altered function as compared to a parent polypeptide. The present invention further provides nucleic acids encoding GlyDH polypeptide variants having altered function as compared to the parent polypeptide. Host cells comprising polynucleotides encoding GlyDH variants and methods of producing lactic acids are also provided in various aspects of the invention.Type: ApplicationFiled: October 4, 2012Publication date: August 21, 2014Inventors: Qingzhao Wang, Keelnatham T. Shanmugam, Lonnie O'Neal Ingram
-
Publication number: 20140234256Abstract: Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided. The genetically engineered cells or microorganisms can be engineered to express a signal and used to interrupt the signaling-dependent virulence of an invading pathogen. The cells or microorganisms can be used to provide signal-dependent expression of a desirable gene in order to interrupt, prevent, and/or ameliorate a disease of mammals, such as parasitic diseases, infectious diseases, autoimmune diseases and genetic disorders.Type: ApplicationFiled: January 9, 2014Publication date: August 21, 2014Applicant: Cornell UniversityInventors: John C. March, Franklin Faping Duan
-
Patent number: 8809036Abstract: The present invention relates to a method for expressing antimicrobial peptide CAD by means of a recombinant Bacillus subtilis expression system. The SUMO protease expression operon is first artificially synthesized. The protein expression operon genes of Saccharomyces cerevisiae small ubiquitin-related protein is then fused with the antibacterial peptide AD. The fusion protein is further cloned into the pNF11 plamid to be introduced into Bacillus subtilis, thereby ensuring the induced expression of recombined Bacillus subtilis in shake flasks. The method has the advantages of a simple expression system, large-scale production, low production cost, strong biological activity and no toxic or harmful substance production. Moreover, the method provides a medicine with low price and strong antibacterial capacity for clinic disease prevention and treatment. This invention can also be used as a feedstuff additive.Type: GrantFiled: July 21, 2009Date of Patent: August 19, 2014Assignee: Peking Sinagri Yin Thai Biotechnology Co. Ltd.Inventors: Shiyan Qiao, Faming Zhu, Wenjiang Guo
-
Publication number: 20140227754Abstract: The present disclosure relates to variants of a parent glucoamylase having altered properties (e.g., improved thermostability and/or specific activity). In particular, the present disclosure provides compositions comprising the variant glucoamylases, including starch hydrolyzing compositions and cleaning compositions. The disclosure also relates to DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.Type: ApplicationFiled: February 4, 2014Publication date: August 14, 2014Applicant: Danisco US Inc.Inventors: Wolfgang Aehle, Richard R. Bott, Martijn Scheffers, Pieter van Solingen, Casper Vroemen
-
Publication number: 20140230096Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2013Publication date: August 14, 2014Applicant: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140227764Abstract: Proteases that comprise an amino acid sequence that is at least 70% identical to the amino acid sequence indicated in SEQ ID NO. 1 over its entire length and that comprise, in the count in accordance with SEQ ID NO. 1, the amino acid substitution R99E or R99D in combination with at least two further amino acid substitutions that are selected from the group consisting of S3T, V4I, and V199I, display very good cleaning performance in particular on blood-containing stains, as well as very good temperature stability.Type: ApplicationFiled: April 25, 2014Publication date: August 14, 2014Applicant: Henkel AG & Co. KGaAInventors: Hendrik Hellmuth, Marion Merkel, Brian Laufs, Susanne Wieland, Timothy O'Connell, Susanne Tondera, Thomas Weber
-
Publication number: 20140227738Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: September 21, 2012Publication date: August 14, 2014Applicant: Novozymes A/SInventors: Jeppe Wegener Tams, Tine Hoff, Morten Gjermansen, Peter Rahbek Oestergaard, Robert Piotr Olinski, Katrine Pontoppidan, Carsten Sjoeholm
-
Publication number: 20140230098Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 27, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140230097Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140227739Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: February 12, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Patent number: 8802420Abstract: Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the Bacillus cereus group that do not produce HBL, HBLa1, HBLa2, or NHE enterotoxins are disclosed. Enterotoxin-deficient mutants are suitable for use as biocontrol agents. Methods for making the mutants and for using the mutants are described.Type: GrantFiled: June 7, 2011Date of Patent: August 12, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Jo Emily Handelsman, Amy Klimowicz, Changhui Guan
-
Patent number: 8802403Abstract: Disclosed herein is a genetic modification of moderately thermophilic Bacillus species that are facultative anaerobic and homolactic. The method includes introducing DNA cloned in a thermosensitive plasmid system containing a pSH71 replicon or a homologue thereof into cells of a moderately thermophilic Bacillus species that is facultative anaerobic and homolactic; culturing the cells on a selective medium at a permissive temperature to select transformed cells; culturing the transformed cells on a selective medium at a non-permissive temperature to select transformed cells capable of growing on the selective medium at the non-permissive temperature. The method can modify the Bacilli for R-lactic acid production, production of other organic acids than lactic acid, alcohol, enzymes, amino acids, and vitamins. The Bacillus species may be modified by replacing the S-lactate dehydrogenase gene by a DNA construct including a DNA sequence encoding R-lactate dehydrogenase.Type: GrantFiled: June 27, 2013Date of Patent: August 12, 2014Assignee: Purac Biochem B.V.Inventors: Richard Van Kranenburg, Mariska Van Hartskamp, Eelco Anthonius Johannes Heintz, Esther Johanna Geertruda Van Mullekom, Jurgen Snelders